Disorders of Coagulation in Stroke

ABSTRACT

The roles of the coagulopathies in thrombosis have been well established; however, the role in ischemic stroke is poorly understood. This article reviews the recent advances in the genetics of coagulation, the recently identified interactive roles of the coagulation and anticoagulation proteins, and the literature supporting protein dysregulation as a causative agent in cerebral venous thrombosis and ischemic stroke.

KEYWORDS

Coagulation - stroke - protein

REFERENCES

• 1 Spronk H M, Govers-Riemslag J W, ten Cate H. The blood coagulation system as a molecular machine.  Bioessays. 2003;  25 1220-1228
• 2 Haberl R L, Biniasch O, Ott M, Peinemann A, Wick M, Kempter B. Infrequency of stroke caused by specific coagulation disorders.  Cerebrovasc Dis. 1995;  5 391-396
• 3 Catto A, Carter A, Ireland H et al.. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke.  Arterioscler Thromb Vasc Biol. 1995;  15 783-785
• 4 Mann K G, Kalafatis M. Factor V: a combination of Dr Jekyll and Mr Hyde.  Blood. 2003;  101 20-30
• 5 Lutze G, Frick U, Topfer G, Urbahn H. Hereditaere Dysprothrombinaemie mit geringer Blutungsneigung (Prothrombin Magdeburg).  Dtsch Med Wochenschr. 1989;  114 288-292
• 6 Poort S R, Rosendaal F R, Reitsma P H, Bertina R M. A common genetic variation in the 3-prime-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.  Blood. 1996;  88 3698-3703
• 7 Dahlbäck B. The discovery of activated protein C resistance.  J Thromb Haemost. 2003;  1 3-9
• 8 Nicolaes G A, Tans G, Thomassen M C et al.. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C.  J Biol Chem. 1995;  270 21158-21166
• 9 Dahlbäck B. The discovery of activated protein C resistance.  J Thromb Haemost. 2003;  1 3-9
• 10 Váradi K, Rosing J, Tans G et al.. Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of factor VIII: influence of the factor V^R506Q mutation.  Thromb Haemost. 1996;  76 208-214
• 11 Thorelli E, Kaufman R J, Dahlbäck B. Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V.  Blood. 1999;  93 2552-2558
• 12 Ridker P M, Miletich J P. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men.  N Engl J Med. 1995;  332 912-917
• 13 Catto A, Carter A, Ireland H et al.. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke.  Arterioscler Thromb Vasc Biol. 1995;  15 783-785
• 14 Press R D, Liu X-Y, Beamer N et al.. Ischaemic stroke in the elderly. Role of the common factor V mutation causing resistance to activated protein C.  Stroke. 1996;  27 44-48
• 15 Castaman G, Tosetto A, Ruggeri M, Rodeghiero F. Pseudohomozygosity for activated protein C resistance is a risk factor for venous thrombosis.  Br J Haematol. 1999;  106 232-236
• 16 Castoldi E, Brugge J M, Nicolaes G A et al.. Impaired APC-cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations.  Blood. 2004;  103 4173-4179
• 17 Bernardi F, Faioni E M, Castoldi E et al.. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype.  Blood. 1997;  90 1552-1557
• 18 Castaman G, Lunghi B, Missiaglia E, Bernardi F, Rodeghiero F. Phenotypic homozygous activated protein C resistance associated with compound heterozygosity for Arg506Gln (factor V Leiden) and His1299Arg substitutions in factor V.  Br J Haematol. 1997;  99 257-261
• 19 Williamson D, Brown K, Luddington R et al.. Factor V Cambridge: a new mutation (Arg306→Thr) associated with resistance to activated protein C.  Blood. 1998;  91 1140-1144
• 20 Chan W P, Lee C K, Kwong Y L et al.. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese.  Blood. 1998;  91 1135-1139
• 21 Gehring N H, Frede U, Neu-Yilik G et al.. Increased efficiency of mRNA 3′ end formation: a new genetic mechanism contributing to hereditary thrombophilia.  Nat Genet. 2001;  28 389-392
• 22 Rosendaal F R. High levels of factor VIII and venous thrombosis.  Thromb Haemost. 2000;  83 1-2
• 23 Bertina R M. Elevated clotting factor levels and venous thrombosis.  Pathophysiol Haemost Thromb. 2003;  33 395-400
• 24 Sebire G, Tabarki B, Saunders D E et al.. Cerebral venous sinus thrombosis in children: risk factors, presentation, diagnosis and outcome.  Brain. 2005;  128 477-489
• 25 Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: a new mutation (Arg306→Thr) associated with resistance to activated protein C.  Blood. 1998;  91 1140-1144
• 26 Kalafatis M, Simioni P, Tormene D et al.. Isolation and characterization of an anti-factor V antibody causing activated protein C resistance from a patient with severe thrombotic manifestations.  Blood. 2002;  99 3985-3992
• 27 Henkens C M, Bom V J, van der Meer J. Lowered APC-sensitivity ratio related to increased factor VIII-clotting activity.  Thromb Haemost. 1995;  74 1198-1199
• 28 Laffan M A, Manning R. The influence of factor VIII on measurement of activated protein C resistance.  Blood Coagul Fibrinolysis. 1996;  7 761-765
• 29 Reitsma P H, Bernardi F, Doig R G et al.. Protein C deficiency: a database of mutations, 1995 update. On behalf of the Subcommittee on Plasma Coagulation Inhibitors of the Scientific and Standardization Committee of the ISTH.  Thromb Haemost. 1995;  73 876-889
• 30 Reitsma P H. Protein C deficiency: summary of the 1995 database update.  Nucleic Acids Res. 1996;  24 157-159
• 31 Gladson C L, Scharrer I, Hach V et al.. The frequency of type 1 heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis.  Thromb Haemost. 1988;  59 18-22
• 32 Grewal R P, Goldberg M A. Stroke in protein C deficiency.  Am J Med. 1990;  89 538-539
• 33 Kohler J, Kasper J, Witt I et al.. Ischaemic stroke due to protein C deficiency.  Stroke. 1990;  21 1077-1080
• 34 Camerlingo M, Finazzi G, Caato L et al.. Inherited protein C deficiency and non-haemorrhagic arterial stroke in young adults.  Neurology. 1991;  41 1371-1373
• 35 Thomas D P, Roberts H R. Hypercoagulability in venous and arterial thrombosis.  Ann Intern Med. 1997;  126 638-644
• 36 Martinelli I, Mannucci P M, De Stefano V et al.. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families.  Blood. 1998;  92 2353-2358
• 37 Kalafatis M, Rand M D, Mann K G. The mechanism of inactivation of human factor V and human factor Va by activated protein C.  J Biol Chem. 1994;  269 31869-31880
• 38 Nicolaes GAF, Tans G, Christella M et al.. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor Va R506Q by activated protein C.  J Biol Chem. 1995;  270 21158-21166
• 39 Heeb M J, Mesters R M, Tans G, Rosing J, Griffin J H. Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C.  J Biol Chem. 1993;  268 2872-2877
• 40 Hackeng T M, van't Veer C, Meijers J C, Bouma B N. Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa.  J Biol Chem. 1994;  269 21051-21058
• 41 Koppelman S J, Hackeng T M, Sixma J J, Bouma B N. Inhibition of the intrinsic factor X activating complex by protein S: evidence for a specific binding of protein S to factor VIII.  Blood. 1995;  86 1062-1071
• 42 van Wijnen M, Stam J G, van't Veer C et al.. The interaction of protein S with the phospholipid surface is essential for the activated protein C-independent activity of protein S.  Thromb Haemost. 1996;  76 397-403
• 43 Dahlbäck B. Protein S and C4b-binding protein: components involved in the regulation of the protein C anticoagulant system.  Thromb Haemost. 1991;  66 49-61
• 44 van de Poel R H, Meijers J C, Bouma B N. C4b-binding protein inhibits the factor V-dependent but not the factor V-independent cofactor activity of protein S in the activated protein C-mediated inactivation of factor VIIIa.  Thromb Haemost. 2001;  85 761-765
• 45 Rezende S M, Simmonds R E, Lane D A. Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S-C4b binding protein complex.  Blood. 2004;  103 1192-1201
• 46 Gandrille S, Borgel D, Sala N et al.. Protein S deficiency: a database of mutations-summary of the first update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.  Thromb Haemost. 2000;  84 918
• 47 Bertina R M. Nomenclature proposal for protein S deficiency. XXXVI Annual meeting of the Scientific and Standardization Committee of the ISTH Barcelona, Spain; 1990
• 48 Israels S J, Seshia S S. Childhood stroke associated with protein C or protein S deficiency.  J Pediatr. 1987;  111 562-564
• 49 Barinagarrementeria F, Cant A, Cant-Brio C et al.. Prothrombotic states in young people with idiopathic stroke: a prospective study.  Stroke. 1994;  25 287-290
• 50 Mayer S A, Sacco R L, Hurlet-Jensen A, Shi T, Mohr J P. Free protein S deficiency in acute ischemic stroke: a case-control study.  Stroke. 1993;  24 224-227
• 51 Kurnik K, Kosch A, Sträter R et al.. Recurrent thromboembolism in infants and children suffering from symptomatic neonatal arterial stroke.  Stroke. 2003;  34 2887-2892
• 52 Green D, Otoya J, Oriba H, Rovner R. Protein S deficiency in middle-aged women with stroke.  Neurology. 1992;  42 1029-1033
• 53 Golub B M, Sibony P A, Coller B S. Protein S deficiency associated with central retinal artery occlusion.  Arch Ophthal. 1990;  108 918
• 54 Hakimi K N, Massagli T L. Anterior spinal artery syndrome in two children with genetic thrombotic disorders.  J Spinal Cord Med. 2005;  28 69-73
• 55 Espinosa-Parrilla Y, Morell M, Souto J C et al.. Protein S gene analysis reveals the presence of a cosegregating mutation in most pedigrees with type I but not type III PS deficiency.  Hum Mutat. 1999;  14 30-39
• 56 Makris M, Leach M, Beauchamp N J et al.. Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis in families with inherited deficiencies of protein S.  Blood. 2000;  95 1935-1941
• 57 Borgel D, Gandrille S, Aiach M. Protein S deficiency.  Thromb Haemost. 1997;  78 351-356
• 58 Restrepo L, McArthur J. Stroke and HIV infection.  Stroke. 2003;  34 e176-e177
• 59 Stahl C P, Wideman C S, Spira T J, Haff E C, Hixon G J, Evatt B L. Protein S deficiency in men with long-term human immunodeficiency virus infection.  Blood. 1993;  81 1801-1807
• 60 Majluf-Cruz A, Silva-Estrada M, Sanchez-Barboza R et al.. Venous thrombosis among patients with AIDS.  Clin Appl Thromb Hemost. 2004;  10 19-25
• 61 Rosenberg R D, Damus P S. The purification and mechanism of action of human antithrombin-heparin cofactor.  J Biol Chem. 1973;  248 6490-6505
• 62 Rosenberg J S, McKenna P W, Rosenberg R D. Inhibition of human factor IXa by human antithrombin.  J Biol Chem. 1975;  250 8883-8888
• 63 Seegers W H, Holt E. An antithrombin reaction related to prothrombin activation.  Am J Physiol. 1954;  176 97
• 64 Biggs R, Denson K W, Akman N, Borrett R, Hadden M. Antithrombin III, antifactor X and heparin.  Br J Haematol. 1970;  19 283-305
• 65 Damus P S, Hicks M, Rosenberg R D. Anticoagulant action of heparin.  Nature. 1973;  246 355-357
• 66 Stead N, Kaplan A, Rosenberg R D. Inhibition of activated factor XII by antithrombin-heparin cofactor.  J Biol Chem. 1976;  251 6481-6488
• 67 Olson S T, Björk I, Sheffer R, Craig P A, Shore J D, Choay J. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement.  J Biol Chem. 1992;  267 12528-12538
• 68 Stein P E, Carrell R W. What do dysfunctional serpins tell us about molecular mobility and disease?.  Nat Struct Biol. 1995;  2 96-113
• 69 Vomberg P P, Breederveld C, Fluery P, Arts W F. Cerebral thromboembolism due to antithrombin III deficiency in two children.  Neuropediatrics. 1987;  18 42-44
• 70 Simioni P, Zanardi S, Saracino A et al.. Occurrence of arterial thrombosis in a cohort of patients with hereditary deficiency of clotting inhibitors.  J Med. 1992;  23 61-64
• 71 Arima T, Motomura M, Nishiura Y et al.. Cerebral infarction in a heterozygous with variant antithrombin III.  Stroke. 1992;  23 1822-1825
• 72 Graham J A, Daly H M, Carson P J. Antithrombin III deficiency and cerebrovascular accidents in young adults.  J Clin Pathol. 1992;  45 921-922
• 73 Martinez H R, Rangel Guerra R A, Marfil L J. Ischemic stroke due to deficiency of coagulation inhibitors: report of 10 young adults.  Stroke. 1993;  24 19-25
• 74 Barinagarrementeria F, Cantu-Brito C, De La Pena A, Izaguirre R. Prothrombotic states in young people with idiopathic stroke. A prospective study.  Stroke. 1994;  25 287-290
• 75 Ernerudh J, Olsson J E, von Schenck H. Antithrombin-III deficiency in ischemic stroke.  Stroke. 1990;  21 967
• 76 Munts A G, van Genderen P J, Dippel D W, van Kooten F, Koudstaal P J. Coagulation disorders in young adults with acute cerebral ischaemia.  J Neurol. 1998;  245 21-25
• 77 Ridker P M, Hennekens C H, Lindpaintner K, Stampfer M J, Eisenberg P R, Miletich J. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men.  N Engl J Med. 1995;  332 912-917
• 78 Markus H S, Hambley H. Neurology and the blood: haematological abnormalities in ischaemic stroke.  J Neurol Neurosurg Psychiatry. 1998;  64 150-159
• 79 Haberl R L, Biniasch O, Ott M, Peinemann A, Wick M, Kempter B. Infrequency of stroke caused by specific coagulation disorders.  Cerebrovasc Dis. 1995;  5 391-396
• 80 Catto A, Carter A, Ireland H et al.. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke.  Arterioscler Thromb Vasc Biol. 1995;  15 783-785
• 81 Press R D, Liu X, Beamer N, Coull B M. Ischemic stroke in the elderly: role of the common factor V mutation causing resistance to activated protein C.  Stroke. 1996;  27 44-48
• 82 Hankey G J, Eikelboom J W, van Bockxmeer F M, Lofthouse E, Staples N, Baker R. Inherited thrombophilia in ischemic stroke and its pathogenic subtypes.  Stroke. 2001;  32 1793-1799
• 83 Jerrard-Dunne P, Evans A, McGovern R et al.. Ethnic differences in markers of thrombophilia: implications for the investigation of ischemic stroke in multiethnic populations: the South London Ethnicity and Stroke Study.  Stroke. 2003;  34 1821-1827
• 84 Martinez H R, Rangel Guerra R A, Marfil L J. Ischemic stroke due to deficiency of coagulation inhibitors: report of 10 young adults.  Stroke. 1993;  24 19-25
• 85 Barinagarrementeria F, Cantu-Brito C, De La Peria A, Izaguirre R. Prothrombotic states in young people with idiopathic stroke: a prospective study.  Stroke. 1994;  25 287-290
• 86 Munts A G, van Genderen P J, Dippel D W, van Kooten F, Koudstaal P J. Coagulation disorders in young adults with acute cerebral ischaemia.  J Neurol. 1998;  245 21-25
• 87 Kroon U B, Silfverstolpe G, Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables.  Thromb Haemost. 1994;  71 420-423
• 88 Shen Y M, Frenkel E P. Thrombosis and a hypercoagulable state in HIV-infected patients.  Clin Appl Thromb Hemost. 2004;  10 277-280